ArticleJournal of contemporary brachytherapy2016

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.

Hideyasu Tsumura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.